Taghizadeh Bita, Ghavami Laleh, Derakhshankhah Hossein, Zangene Ehsan, Razmi Mahdieh, Jaymand Mehdi, Zarrintaj Payam, Zarghami Nosratollah, Jaafari Mahmoud Reza, Moallem Shahri Matin, Moghaddasian Adrineh, Tayebi Lobat, Izadi Zhila
Department of Medical Biotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Laboratory of Biophysics and Molecular Biology, Department of Biophysics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Front Bioeng Biotechnol. 2020 Dec 9;8:529244. doi: 10.3389/fbioe.2020.529244. eCollection 2020.
Valvular heart disease (VHD) occurs as the result of valvular malfunction, which can greatly reduce patient's quality of life and if left untreated may lead to death. Different treatment regiments are available for management of this defect, which can be helpful in reducing the symptoms. The global commitment to reduce VHD-related mortality rates has enhanced the need for new therapeutic approaches. During the past decade, development of innovative pharmacological and surgical approaches have dramatically improved the quality of life for VHD patients, yet the search for low cost, more effective, and less invasive approaches is ongoing. The gold standard approach for VHD management is to replace or repair the injured valvular tissue with natural or synthetic biomaterials. Application of these biomaterials for cardiac valve regeneration and repair holds a great promise for treatment of this type of heart disease. The focus of the present review is the current use of different types of biomaterials in treatment of valvular heart diseases.
心脏瓣膜病（VHD）是由瓣膜功能障碍引起的，这会极大地降低患者的生活质量，若不治疗可能导致死亡。针对这种缺陷有不同的治疗方案，有助于减轻症状。全球致力于降低与VHD相关的死亡率，这增加了对新治疗方法的需求。在过去十年中，创新的药物和手术方法的发展显著改善了VHD患者的生活质量，但人们仍在寻找低成本、更有效且侵入性更小的方法。VHD管理的金标准方法是用天然或合成生物材料替换或修复受损的瓣膜组织。这些生物材料在心脏瓣膜再生和修复中的应用为治疗这类心脏病带来了巨大希望。本综述的重点是不同类型生物材料在心脏瓣膜病治疗中的当前应用。
